In fact, IRE1α inhibition sensitizes PD-L1-TP53-mutant, immunologically ‘cold’ TNBCs to chemo-immunotherapy, and IRE1α inhibition works synergistically with an anti-angiogenic, anti-VEGF-A antibody [198] to cause tumor regression in TNBC cells [199]. The gene discussed is CD274; the disease is neoplasm.